Some studies have shown that CCR2 may affect the development of melanoma by regulating immune cell migration and inflammatory response.[31,32] Sabino Strippoli et al have shown that circulating CD4−/CD8− double negative T cells change during checkpoint inhibitor therapy and may be good at sensing the immune response to melanoma. The gene discussed is CD8A; the disease is melanoma.